

Amendment of the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently Amended) A process for extending lifespan of a mouse, a human, or a cell thereof mammal or a mammalian cell beyond a generic expected lifespan for said mouse, said human, or said cell thereof mammal or mammalian cell comprising administering to said mouse, said human, or said cell thereof mammal or mammalian cell a therapeutically effective amount of a composition comprising a C₆₀ compound or a combination of such C₆₀ compounds, said C₆₀ compounds being selected from the group consisting of *e,e,e* C₆₀(C(COOH)₂)₂(CHCOOH), *e,e,e* C₆₀(CHCOOH)₃, C₆₀(C(COOH)₂)_n, pharmaceutically acceptable salts of any of the foregoing, pharmaceutically acceptable esters of any of the foregoing, and pharmaceutically acceptable amides of any of the foregoing, wherein the C adjacent the C₆₀ moiety in each of the foregoing formulae is directly bonded to two adjacent carbons of the C₆₀ moiety, wherein n = 1, 2, or 3, and wherein said mouse, said human, or said cell thereof mammal or mammalian cell is not selected for a disability, thereby extending the lifespan of said mouse, said human, or said cell thereof mammal or said mammalian cell beyond the generic expected lifespan for said mouse, said human, or said cell thereof mammal or said mammalian cell by up to about 20% [[32%]].
3. (Previously Presented) The process of Claim 1 wherein said at least one said C₆₀ compound is administered in a composition further comprising a pharmaceutically acceptable carrier.
4. (Previously Presented) The process of Claim 1 where n is 3.

5. (Previously Presented) The process of Claim 4 wherein said C₆₀ compound is
e,e,e C₆₀(C(COOH)₂)₃.

6. (Previously Presented) The process of Claim 1 wherein said C₆₀ compound is
administered intravenously, intramuscularly, subcutaneously or orally.

7. (Previously Presented) The process of Claim 6 wherein said C₆₀ compound is
administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1
mg/kg.

8. (Previously Presented) The process of Claim 7 wherein said C₆₀ compound is
administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.

9. (Previously Presented) The process of Claim 6 wherein said C₆₀ compound is
administered orally in an amount of at least 0.1 mg/kg.

10. (Previously Presented) The process of Claim 6 wherein said C₆₀ compound is
administered orally in an amount of about 15 mg/kg.

11. (Previously Presented) The process of Claim 7 wherein said C₆₀ compound is
administered daily.

12. (Previously Presented) The process of Claim 9 wherein said C₆₀ compound is
administered daily.

13.-69. (Canceled)

70. (Currently Amended) The process as set forth in Claim 1 wherein an expected
lifespan of said mouse, said human, or said cell thereof ~~the mammal or mammalian cell~~ prior to
treatment is the generic expected lifespan for said mouse, said human, or said cell thereof
~~mammal or mammalian cell~~.